<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02708459</url>
  </required_header>
  <id_info>
    <org_study_id>Abuelella TAP</org_study_id>
    <nct_id>NCT02708459</nct_id>
  </id_info>
  <brief_title>Transversus Abdominus Plane Block in Living Donor Hepatectomy</brief_title>
  <acronym>TAP Donor</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>AlRefaey Kandeel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing different drugs used in Transversus abdominus plane analgesia after donor
      hepatectomy. Patients will be divided into three groups; control group, Bupivecaine group,
      and Dexmedetomedine group according to the used drug
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transversus abdominus plane block for postoperative analgesia after donor hpatectomy surgery
      using three different drugs control group, Bupivecaine group, and Dexmedetomedine group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative morphine (mg) consumption in 1st 48 hours</measure>
    <time_frame>48 hours postoperative</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Living Donor Hepatectomy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupevecaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>surgically inserted Transversus abdominus plane catheter</intervention_name>
    <description>at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle</description>
    <arm_group_label>Bupevecaine group</arm_group_label>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous morphine</intervention_name>
    <description>Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Bupevecaine group</arm_group_label>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupevecaine</intervention_name>
    <arm_group_label>Bupevecaine group</arm_group_label>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomedine</intervention_name>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all living hepatectomy donors in Mansoura liver transplantation program

        Exclusion Criteria:

          -  refusal known sensetivity to used drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mansoura university</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahleya</state>
        <zip>62215</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura university</name>
      <address>
        <city>Mansoura</city>
        <state>Dkahleya</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>AlRefaey Kandeel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

